Stockscreener 앱 받기
13.09
1.39%
0.18
시간 외 거래:
13.05
-0.04
-0.31%
전일 마감가:
$12.91
열려 있는:
$12.94
하루 거래량:
213.38K
Relative Volume:
0.14
시가총액:
$203.09M
수익:
$10.73M
순이익/손실:
$-455.74M
주가수익비율:
-5.5116
EPS:
-2.375
순현금흐름:
$-502.70M
1주 성능:
+0.77%
1개월 성능:
-4.24%
6개월 성능:
-81.24%
1년 성능:
-50.15%
1일 변동 폭
$12.80
$13.30
1주일 범위
$12.71
$13.57
52주 변동 폭
$11.95
$73.06
어비디티 바이오사이언스 Stock (RNA) Company Profile
Compare RNA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNA
Atrium Therapeutics Inc
|
13.09 | 200.30M | 10.73M | -455.74M | -502.70M | -2.375 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
어비디티 바이오사이언스 Stock (RNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-11 | 개시 | Wells Fargo | Overweight |
| 2025-09-17 | 개시 | Roth Capital | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Bernstein | Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-06-11 | 개시 | Raymond James | Strong Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-20 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-09-24 | 개시 | Goldman | Buy |
| 2024-08-28 | 개시 | Barclays | Overweight |
| 2024-05-03 | 개시 | BofA Securities | Buy |
| 2024-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-05-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Strong Buy |
| 2021-09-07 | 개시 | Evercore ISI | Outperform |
| 2021-06-17 | 개시 | Needham | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | Cowen | Outperform |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | SVB Leerink | Outperform |
| 2020-07-07 | 개시 | Wells Fargo | Overweight |
모두보기
어비디티 바이오사이언스 주식(RNA)의 최신 뉴스
RNA 260618 33.00P (RNA260618P33000) Stock Options Chain | Quotes & News - Moomoo
Fierce Biotech Fundraising Tracker '26: Vivacta snags $50M+ series A; Coultreon reels in $125M - Fierce Biotech
Atrium Therapeutics (RNA) price target decreased by 65.57% to 25.50 - MSN
BlackRock (NASDAQ: RNA) reports 5.2% stake — 892,387 shares - Stock Titan
Atrium Therapeutics, Inc. (RNA) - DirectorsTalk Interviews
Milestone in Atrium and BMS cardiovascular collaboration - BioWorld News
BMY Secures $15M Milestone Payment to Atrium Therapeutics - GuruFocus
Atrium Therapeutics earns $15M from Bristol Myers Squibb By Investing.com - Investing.com South Africa
Atrium Therapeutics earns $15M from Bristol Myers Squibb - Investing.com
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration - PR Newswire
RNA SEC FilingsAtrium Therapeutics, Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RNA (Atrium Therapeutics Inc.) posts 70.8 percent year over year Q1 2026 revenue growth, shares rise 3.71 percent. - Xã Thanh Hà
Atrium Therapeutics grants RSUs and options to executive | RNA Insider Trading - Stock Titan
[Form 4] Atrium Therapeutics, Inc. Insider Trading Activity - Stock Titan
Atrium Therapeutics (RNA) CFO awarded 30,000 RSUs and 60,000 stock options - Stock Titan
Atrium Therapeutics (RNA) director Gallagher granted RSUs and 205,000-share option - Stock Titan
Atrium Therapeutics (RNA) CSO awarded 30,000 RSUs and 60,000 options - Stock Titan
Atrium Therapeutics (RNA) CSO granted RSUs and 60,000 stock options in Form 4 - Stock Titan
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Month - Sahm
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network
Omdia: India’s smartphone shipments fell 5% in 1Q26 amid channel caution and pricing pressures - Weekly Voice
Atrium offers stock awards to 7 new hires under Nasdaq rule - Stock Titan
Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Grand Junction Daily Sentinel
Form S-8Securities to be offered to employees in employee benefit plans - ADVFN
Atrium Therapeutics Inc - Reuters
Atrium Therapeutics Inc. Live Share Prices and Trades. RNA.US Live Streaming Share Prices. - London South East
Is Atrium Therapeutics (RNA) Stock Declining | Price at $13.72, Up 0.15%Reversal Setup - Newser
T. Rowe Price holds 1.55M Atrium shares (10.0%) (NASDAQ: RNA) - Stock Titan
Is Atrium Therapeutics (RNA) Stock Worth Buying Now | Price at $13.77, Up 2.46%Pro Trader Recommendations - Newser
RNA Rallies on Expansion News - Newser
Stock List: Research Stocks from Around the World - GuruFocus
Atrium Therapeutics Inc. (RNA) Stock Price Quote Today & Current Price Chart - Capital.com
Atrium Therapeutics Inc. (RNA) Stock Price Quote Today & Current Price Chart | Capital.com Australia - capital.com
RNA PE Ratio & Valuation, Is RNA Overvalued - Intellectia AI
Mast Multialternative Strategy Fund's Atrium Therapeutics Inc(RNA) Holding History - GuruFocus
Atrium Therapeutics, Inc. (RNA): Investor Outlook On A Potential 90% Upside - DirectorsTalk Interviews
Atrium Therapeutics, Inc.(NasdaqGS:RNA) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
RNA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Stephanie Kenney Net Worth (2026) - GuruFocus
Novartis acquisition spin-off pioneers RNA therapeutics for the heart - Pharma Voice
Rocio Martin Hoyos Net Worth (2026) - GuruFocus
Brendan R. Winslow Net Worth (2026) - gurufocus.com
Atrium Mortgage Investment (TSE:AI) Given a C$13.12 Price Target at Fundamental Research - Defense World
Atrium Therapeutics, Inc.: Revenue and Earnings Analysts Forecasts Revisions | RNA | US04965N1046 - marketscreener.com
Finance Watch: Market Struggles On Iran War, Jobs Data, Impacting Biopharma Stocks - Citeline News & Insights
Atrium Therapeutics Inc. (NASDAQ: RNA)Share Price and Research - intelligentinvestor.com.au
Tenaya, Alnylam join in $1B+ cardio deal for novel genetic targets - BioWorld MedTech
Rx Rundown: EveryOne Medicines, Atrium Therapeutics, Moderna and more - Medical Marketing and Media
Atrium Therapeutics Inc Share Price USD0.001 - Hargreaves Lansdown
Atrium Therapeutics born from Novartis-Avidity deal to pioneer RNA therapies - BioXconomy
어비디티 바이오사이언스 (RNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):